<DOC>
	<DOC>NCT01859455</DOC>
	<brief_summary>This study is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of LGT209 in hypercholesterolemic patients taking common statin medications and in healthy volunteers.</brief_summary>
	<brief_title>Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Healthy volunteers: Male and female subjects 18 to 70 years of age, in general good health with fasting LDLcholesterol &gt;90 mg/dL and fasting serum triglycerides &lt;400 mg/dL Patients on statin therapy: Male and female patients 18 to 70 years of age receiving atorvastatin or simvastatin and with fasting LDLcholesterol &gt;90 mg/dL and fasting serum triglycerides &lt;400 mg/dL Healthy volunteers: History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes Women of childbearing potential unless using highly effective methods of contraception Conditions which might impact the safety or biologic activity of the study drug Statin patients: Use of concomitant medications known to impact the safe use or efficacy of atorvastatin and simvastatin based on drug labels Women of childbearing potential unless using highly effective methods of contraception during dosing and for at least 100 days after study drug administration Conditions which might impact the safety or biologic activity of the study drug Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hypercholesterolemia,</keyword>
	<keyword>LDL cholesterol lowering,</keyword>
	<keyword>proprotein convertase subtilisin/kexin type 9 (PCSK9),</keyword>
	<keyword>LGT209,</keyword>
	<keyword>drug safety,</keyword>
	<keyword>pharmacokinetics,</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>